JP2021527713A - 増殖性細胞を抑制する方法 - Google Patents

増殖性細胞を抑制する方法 Download PDF

Info

Publication number
JP2021527713A
JP2021527713A JP2021519532A JP2021519532A JP2021527713A JP 2021527713 A JP2021527713 A JP 2021527713A JP 2021519532 A JP2021519532 A JP 2021519532A JP 2021519532 A JP2021519532 A JP 2021519532A JP 2021527713 A JP2021527713 A JP 2021527713A
Authority
JP
Japan
Prior art keywords
nucleic acid
wrn
proliferative
agent
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527713A5 (https=
JPWO2019241802A5 (https=
Inventor
リサ、ベルモント
ジェフ、ハーガー
裕次郎 畑
ローン、カテガヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ideaya Biosciences Inc
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of JP2021527713A publication Critical patent/JP2021527713A/ja
Publication of JP2021527713A5 publication Critical patent/JP2021527713A5/ja
Publication of JPWO2019241802A5 publication Critical patent/JPWO2019241802A5/ja
Priority to JP2024109073A priority Critical patent/JP2024153667A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021519532A 2018-06-15 2019-06-17 増殖性細胞を抑制する方法 Pending JP2021527713A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024109073A JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685866P 2018-06-15 2018-06-15
US62/685,866 2018-06-15
PCT/US2019/037559 WO2019241802A2 (en) 2018-06-15 2019-06-17 Methods of inhibiting proliferative cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024109073A Division JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Publications (3)

Publication Number Publication Date
JP2021527713A true JP2021527713A (ja) 2021-10-14
JP2021527713A5 JP2021527713A5 (https=) 2022-06-27
JPWO2019241802A5 JPWO2019241802A5 (https=) 2022-06-27

Family

ID=67138135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519532A Pending JP2021527713A (ja) 2018-06-15 2019-06-17 増殖性細胞を抑制する方法
JP2024109073A Pending JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024109073A Pending JP2024153667A (ja) 2018-06-15 2024-07-05 増殖性細胞を抑制する方法

Country Status (4)

Country Link
US (1) US20210371855A1 (https=)
EP (1) EP3806850A2 (https=)
JP (2) JP2021527713A (https=)
WO (1) WO2019241802A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236448A1 (en) 2018-06-04 2019-12-12 The Broad Institute, Inc. Therapeutic treatment of microsatellite unstable cancers
WO2025239377A1 (ja) * 2024-05-16 2025-11-20 株式会社ジーンケア研究所 ＷＲＮヘリカーゼ遺伝子を標的とするｓｉＲＮＡ

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7714162B6 (ja) * 2018-12-03 2025-09-08 タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
JP2024508841A (ja) * 2021-02-25 2024-02-28 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ プログラム可能なタンパク質分解のための化合物及び疾患処置のための使用方法
JP7753397B2 (ja) * 2021-05-26 2025-10-14 ノバルティス アーゲー ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体
WO2023062575A1 (en) * 2021-10-14 2023-04-20 Ideaya Biosciences, Inc. Cyclic vinyl sulfone compounds as wrn inhibitors
KR20250034120A (ko) * 2022-07-06 2025-03-10 비비디온 테라퓨틱스, 인코포레이티드 Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물
TW202421158A (zh) 2022-11-18 2024-06-01 瑞士商諾華公司 藥物組合及其用途
WO2024140597A1 (zh) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Wrn解旋酶抑制剂
CN120603834A (zh) * 2023-01-18 2025-09-05 成都微芯药业有限公司 双杂环wrn抑制剂、其制备方法及其应用
WO2024153244A1 (zh) * 2023-01-20 2024-07-25 南京再明医药有限公司 含氮类化合物
WO2024215923A2 (en) * 2023-04-11 2024-10-17 Nimbus Wadjet, Inc. Cyclic vinyl sulfone wrn inhibitors
WO2024235844A1 (en) * 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
TW202510857A (zh) * 2023-06-01 2025-03-16 英商葛蘭素史密斯克藍智慧財產權有限公司 化合物及其用途
WO2025026382A1 (zh) * 2023-08-01 2025-02-06 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025106693A1 (en) * 2023-11-16 2025-05-22 Eikon Therapeutics, Inc. Methods and compositions for treating cancers with high microsatellite instability levels
WO2025131978A1 (en) * 2023-12-20 2025-06-26 Nerviano Medical Sciences S.R.L. Drug-linker reagents for conjugation
WO2025237361A1 (zh) * 2024-05-16 2025-11-20 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025252190A1 (en) * 2024-06-07 2025-12-11 Cullgen Inc. Targeted degraders of werner syndrome recq helicase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068690A1 (en) * 2001-02-23 2002-09-06 Isis Pharmaceuticals, Inc. Antisense modulation of wrn expression
JP2012219085A (ja) * 2011-04-13 2012-11-12 Shiga Univ Of Medical Science 頭頸部癌及び食道癌用抗癌剤及び増強剤
JP2015516144A (ja) * 2012-04-10 2015-06-08 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 癌におけるマイクロサテライト不安定性を検出しｄｎａ塩基除去修復経路の阻害による合成致死性を決定するための新規なマーカー

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372772B1 (en) * 1997-08-01 2002-04-16 Prolx Pharmaceuticals Corporation Inhibitors of redox signaling and methods of using same
WO2002024692A1 (en) * 2000-09-20 2002-03-28 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
US7659278B2 (en) * 2002-02-21 2010-02-09 Aprea Ab Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
EP1761629A2 (en) * 2004-05-19 2007-03-14 Trustees Of Boston University Modulation of wrn-mediated telomere-initiated cell signaling
WO2011014825A2 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
CA2951816A1 (en) * 2013-06-12 2014-12-18 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
US20190185849A1 (en) 2016-06-29 2019-06-20 Crispr Therapeutics Ag Compositions and methods for gene editing
US11530413B2 (en) * 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
MX2020013120A (es) * 2018-06-04 2021-07-21 Broad Inst Inc Tratamiento terapéutico de cánceres de microsatélites inestables.
JP7753397B2 (ja) * 2021-05-26 2025-10-14 ノバルティス アーゲー ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068690A1 (en) * 2001-02-23 2002-09-06 Isis Pharmaceuticals, Inc. Antisense modulation of wrn expression
JP2012219085A (ja) * 2011-04-13 2012-11-12 Shiga Univ Of Medical Science 頭頸部癌及び食道癌用抗癌剤及び増強剤
JP2015516144A (ja) * 2012-04-10 2015-06-08 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 癌におけるマイクロサテライト不安定性を検出しｄｎａ塩基除去修復経路の阻害による合成致死性を決定するための新規なマーカー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AGGARWAL M; ET AL: "INHIBITION OF HELICASE ACTIVITY BY A SMALL MOLECULE IMPAIRS WERNER SYNDROME HELICASE 以下備考", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. VOL:108, NR:4,, JPN5021010609, 10 January 2011 (2011-01-10), US, pages 1525 - 1530, ISSN: 0005278953 *
KAZUNOBU FUTAMI; ET AL: "RECQL1 AND WRN DNA REPAIR HELICASES: POTENTIAL THERAPEUTIC TARGETS AND PROLIFERATIVE 以下備考", FRONTIERS IN GENETICS, vol. VOL:5, NR:441,, JPN5021010608, 2015, pages 1 - 11, ISSN: 0005278954 *
R. MOLES; ET AL: "WRN-TARGETED THERAPY USING INHIBITORS NSC 19630 AND NSC 617145 INDUCE APOPTOSIS IN 以下備考", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, no. 121, JPN5021010610, 9 November 2016 (2016-11-09), pages 1 - 11, ISSN: 0005077442 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236448A1 (en) 2018-06-04 2019-12-12 The Broad Institute, Inc. Therapeutic treatment of microsatellite unstable cancers
WO2025239377A1 (ja) * 2024-05-16 2025-11-20 株式会社ジーンケア研究所 ＷＲＮヘリカーゼ遺伝子を標的とするｓｉＲＮＡ

Also Published As

Publication number Publication date
WO2019241802A2 (en) 2019-12-19
WO2019241802A3 (en) 2020-01-23
EP3806850A2 (en) 2021-04-21
JP2024153667A (ja) 2024-10-29
US20210371855A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JP2021527713A (ja) 増殖性細胞を抑制する方法
CN110959039B (zh) 新型cas13b直向同源物crispr酶和系统
US10407734B2 (en) Compositions and methods of using transposons
Reynolds et al. Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers
JP6081798B2 (ja) ｍｉＲＮＡに関連する癌を検出および処置するための方法および組成物およびｍｉＲＮＡインヒビターおよび標的
JP5886757B2 (ja) インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
CN111448318A (zh) 修饰在真核细胞中用于沉默基因表达的非编码rna分子的特异性的方法
US20050288243A1 (en) Methods and compositions for treating gain-of-function disorders using RNA interference
US20210171958A1 (en) Methods of treating cancer
US20160130663A1 (en) Method for predicting response to cancer treatment
EP3430143B1 (en) Inhibitors of srsf1 to treat neurodegenerative disorders
JPWO2012008301A1 (ja) ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
EP2972381A2 (en) Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
KR101908593B1 (ko) Cftr 유전자 소실 유도 가이드 rna, cftr 변이를 갖는 t84 세포 및 이의 용도
WO2016098873A1 (ja) 中枢神経原発悪性リンパ腫の発症リスクを判定する方法及び中枢神経原発悪性リンパ腫の治療用組成物
US20070135368A1 (en) Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
JP2025532225A (ja) Ｔ細胞操作を改善するための遺伝毒性ストレスの阻害
JP7650082B2 (ja) 核酸構築物、及び該核酸構築物を含むミスマッチ修復欠損がんの治療剤又は診断剤
US20250257357A1 (en) Treatment of h3.3-mutant brain cancer with pnkp inhibitors
WO2010024405A1 (ja) Ｉ型ｉｆｎの産生阻害剤、及びその探索方法
WO2008126085A2 (en) Method for treating bone marrow disorders
Lenko Functional Characterization of Germline Smg1 Mutations Associated With Pancreatic Ductal Adenocarcinoma
Neumann The multifaceted role of mutant p53 in remodeling the tumor transcriptome and secretome
Gaballa PAF1c drives MYC-mediated immune evasion in pancreatic ductal adenocarcinoma
JP2026501822A (ja) 癌における細胞致死性の誘導

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240308